Literature DB >> 19090876

Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

William C Cushman1, Charles E Ford, Paula T Einhorn, Jackson T Wright, Richard A Preston, Barry R Davis, Jan N Basile, Paul K Whelton, Robert J Weiss, Arnaud Bastien, Donald L Courtney, Bruce P Hamilton, Kent Kirchner, Gail T Louis, Tamrat M Retta, Donald G Vidt.   

Abstract

Blood pressure (BP) control rates and number of antihypertensive medications were compared (average follow-up, 4.9 years) by randomized groups: chlorthalidone, 12.5-25 mg/d (n=15,255), amlodipine 2.5-10 mg/d (n=9048), or lisinopril 10-40 mg/d (n=9054) in a randomized double-blind hypertension trial. Participants were hypertensives aged 55 or older with additional cardiovascular risk factor(s), recruited from 623 centers. Additional agents from other classes were added as needed to achieve BP control. BP was reduced from 145/83 mm Hg (27% control) to 134/76 mm Hg (chlorthalidone, 68% control), 135/75 mm Hg (amlodipine, 66% control), and 136/76 mm Hg (lisinopril, 61% control) by 5 years; the mean number of drugs prescribed was 1.9, 2.0, and 2.1, respectively. Only 28% (chlorthalidone), 24% (amlodipine), and 24% (lisinopril) were controlled on monotherapy. BP control was achieved in the majority of each randomized group-a greater proportion with chlorthalidone. Over time, providers and patients should expect multidrug therapy to achieve BP <140/90 mm Hg in a majority of patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19090876      PMCID: PMC2897821          DOI: 10.1111/j.1751-7176.2008.00015.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  27 in total

1.  Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.

Authors:  Michael E Ernst; Barry L Carter; Chris J Goerdt; Jennifer J G Steffensmeier; Beth Bryles Phillips; M Bridget Zimmerman; George R Bergus
Journal:  Hypertension       Date:  2006-01-23       Impact factor: 10.190

2.  Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.

Authors:  Jackson T Wright; J Kay Dunn; Jeffrey A Cutler; Barry R Davis; William C Cushman; Charles E Ford; L Julian Haywood; Frans H H Leenen; Karen L Margolis; Vasilios Papademetriou; Jeffrey L Probstfield; Paul K Whelton; Gabriel B Habib
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

3.  Inadequate management of blood pressure in a hypertensive population.

Authors:  D R Berlowitz; A S Ash; E C Hickey; R H Friedman; M Glickman; B Kader; M A Moskowitz
Journal:  N Engl J Med       Date:  1998-12-31       Impact factor: 91.245

4.  The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience.

Authors:  J T Wright; W C Cushman; B R Davis; J Barzilay; P Colon; D Egan; T Lucente; C Nwachuku; S Pressel; F H Leenen; J Frolkis; R Letterer; S Walsh; J N Tobin; G E Deger
Journal:  Control Clin Trials       Date:  2001-12

5.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

6.  Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

Authors:  Kwok Leung Ong; Bernard M Y Cheung; Yu Bun Man; Chu Pak Lau; Karen S L Lam
Journal:  Hypertension       Date:  2006-12-11       Impact factor: 10.190

7.  How do minor changes in the definition of blood pressure control affect the reported success of hypertension treatment?

Authors:  Beverly B Green; Robert C Kaplan; Bruce M Psaty
Journal:  Am J Manag Care       Date:  2003-03       Impact factor: 2.229

8.  The burden of adult hypertension in the United States 1999 to 2000: a rising tide.

Authors:  Larry E Fields; Vicki L Burt; Jeffery A Cutler; Jeffrey Hughes; Edward J Roccella; Paul Sorlie
Journal:  Hypertension       Date:  2004-08-23       Impact factor: 10.190

9.  Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents.

Authors:  B J Materson; D J Reda; W C Cushman; W G Henderson
Journal:  J Hum Hypertens       Date:  1995-10       Impact factor: 3.012

10.  Assessment of factors influencing blood pressure control in a managed care population.

Authors:  Tanya M Romain; Rosalie P Patel; Andrea M Heaberlin; Barbara J Zarowitz
Journal:  Pharmacotherapy       Date:  2003-08       Impact factor: 4.705

View more
  38 in total

1.  The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.

Authors:  Shizuka Aritomi; Hajime Koganei; Hirotaka Wagatsuma; Akira Mitsui; Tetsuya Ogawa; Kosaku Nitta; Tomoyuki Konda
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

Review 2.  Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications.

Authors:  Graziela Z Kalil; William G Haynes
Journal:  Hypertens Res       Date:  2011-11-03       Impact factor: 3.872

3.  Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study.

Authors:  Richard Sherva; Charles E Ford; John H Eckfeldt; Barry R Davis; Eric Boerwinkle; Donna K Arnett
Journal:  Stroke       Date:  2010-12-23       Impact factor: 7.914

4.  Hypertension control among newly treated patients before and after publication of the main ALLHAT results and JNC 7 guidelines.

Authors:  Marie Krousel-Wood; Paul Muntner; April Carson; Amanda H Anderson; Erin Delaune; William C Cushman; Jeffrey A Cutler; Linda B Piller; Gary A Goforth; Paul K Whelton
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-03-16       Impact factor: 3.738

5.  Blood Pressure Management in Intracranial Hemorrhage: Current Challenges and Opportunities.

Authors:  Cheryl Carcel; Shoichiro Sato; Craig S Anderson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-04

6.  State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors.

Authors:  Oni J Blackstock; Karen H Wang; David A Fiellin
Journal:  J Gen Intern Med       Date:  2011-08-12       Impact factor: 5.128

7.  Obstructive sleep apnea and cardiovascular disease in blacks: a call to action from the Association of Black Cardiologists.

Authors:  Oladipupo Olafiranye; Olakunle Akinboboye; Judith E Mitchell; Gbenga Ogedegbe; Girardin Jean-Louis
Journal:  Am Heart J       Date:  2013-02-19       Impact factor: 4.749

Review 8.  Research Needs to Improve Hypertension Treatment and Control in African Americans.

Authors:  Paul K Whelton; Paula T Einhorn; Paul Muntner; Lawrence J Appel; William C Cushman; Ana V Diez Roux; Keith C Ferdinand; Mahboob Rahman; Herman A Taylor; Jamy Ard; Donna K Arnett; Barry L Carter; Barry R Davis; Barry I Freedman; Lisa A Cooper; Richard Cooper; Patrice Desvigne-Nickens; Nara Gavini; Alan S Go; David J Hyman; Paul L Kimmel; Karen L Margolis; Edgar R Miller; Katherine T Mills; George A Mensah; Ann M Navar; Gbenga Ogedegbe; Michael K Rakotz; George Thomas; Jonathan N Tobin; Jackson T Wright; Sung Sug Sarah Yoon; Jeffrey A Cutler
Journal:  Hypertension       Date:  2016-09-12       Impact factor: 10.190

9.  Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D.

Authors:  Paulette D Chandler; Jamil B Scott; Bettina F Drake; Kimmie Ng; John P Forman; Andrew T Chan; Gary G Bennett; Bruce W Hollis; Edward L Giovannucci; Karen M Emmons; Charles S Fuchs
Journal:  Am J Med       Date:  2014-03-20       Impact factor: 4.965

10.  Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.

Authors:  Amy I Lynch; Eric Boerwinkle; Barry R Davis; Charles E Ford; John H Eckfeldt; Catherine Leiendecker-Foster; Donna K Arnett
Journal:  Pharmacogenet Genomics       Date:  2009-06       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.